Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis. The global myasthenia gravis treatment market size ...
Patients with cold agglutinin disease (CAD) had durable responses at week 53, and no new safety signals were reported. Newly released data from the CARDINAL study of sutimlimab (Enjaymo) for the ...
The classical pathway is activated by C1q-mediated recognition of the target. Further activation of this pathway causes C4b and its cleavage product iC4b to accumulate in the tissues. C4b binds to C2 ...
The mannose-binding lectin pathway can be activated by C3 hydrolysis or antigens without the presence of antibodies (non-specific immune response). In all three pathways, C3-convertase cleaves and ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 27 (Jul. 6, 2004), pp. 10127-10131 (5 pages) The lectin complement pathway in innate immunity is closely ...
A newly published case report suggests sutimlimab (Enjaymo) may be an effective treatment for some patients with warm autoimmune hemolytic anemia (wAIHA). Sutimlimab is a humanized monoclonal antibody ...
Amyloid-β (Aβ) plaques and neurofibrillary tangles are the main pathological hallmarks of Alzheimer's disease, as well as the loss of neurons and synapses. recent reports have shown that estrogen ...
The mannose-binding lectin pathway can be activated by C3 hydrolysis or antigens without the presence of antibodies (non-specific immune response). In all three pathways, C3-convertase cleaves and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback